Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 24;25(1):138.
doi: 10.1186/s12885-025-13572-8.

Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan

Shuya Kandori  1 , Shuhei Suzuki  2 , Kosuke Kojo  2 , Bunpei Isoda  2 , Takazo Tanaka  2 , Satoshi Nitta  2 , Masanobu Shiga  2 , Yoshiyuki Nagumo  2 , Atsushi Ikeda  2 , Takashi Kawahara  2 , Akio Hoshi  2 , Hiromitsu Negoro  2 , Bryan J Mathis  3 , Ayako Okuyama  4   5 , Hiroyuki Nishiyama  2
Affiliations

Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan

Shuya Kandori et al. BMC Cancer. .

Abstract

Background: To identify the prognosis of Japanese patients with collecting duct carcinoma (CDC).

Methods: We used a hospital-based cancer registry data in Japan to extract CDC cases that were diagnosed in 2013, histologically confirmed, and determined the first course of treatment. We further investigated treatment modalities and estimated overall survival (OS) by the Kaplan-Meier method.

Results: A total of 61 CDC patients were identified. The 5-year OS rate for all CDC patients who were diagnosed in Japan during 2013 was 23.6% (95% CI: 15.0-37.4), with a median OS of 14 months (95% CI: 12-24). The 5-year OS rate for CDC patients at stages I, III, and IV were 53.0% (95% CI: 29.9-94.0), 35.7% (95% CI: 19.8-64.4), and 3.4% (95% CI: 0.5-23.7), respectively. Noteworthy, the 1-year OS for stage IV patients was 27.6% (95% CI: 0.5-23.7) and the median OS was only 5 months (95% CI: 4-12). We further examined the OS for advanced disease according to treatment modalities. The median OS of patients who undertook chemotherapy alone was significantly shorter than patients who undertook surgery alone for advanced disease (4 months [95% CI: 4-NA] vs. 15 months [95% CI: 13-68]; p < 0.001) and surgery-only patients had a similar median OS as surgery-plus-chemotherapy patients (19 months [95% CI: 13-NA]; p < 0.001). Moreover, a multivariable analysis for the OS in advanced disease revealed that surgery-plus-chemotherapy patients had significantly more favorable prognoses (HR 0.21, 95% CI: 0.07-0.57).

Conclusions: Japanese CDC patients face poor prognoses similar to Western countries, especially in advanced cases that receive only chemotherapy. Surgery appears necessary for advanced disease.

Keywords: Collecting duct carcinoma; Hospital-based cancer registry; Overall survival; Renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study protocol and data processing were approved by the University of Tsukuba Institutional Review Board (R03-228). All patients gave written, informed consent. All methods were performed under the Declaration of Helsinki and the Guideline of the University of Tsukuba. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Eligibility of patients with CDC
Fig. 2
Fig. 2
Kaplan–Meier analyses of OS for all patients
Fig. 3
Fig. 3
Kaplan–Meier analyses of OS, stratified by stage
Fig. 4
Fig. 4
Patterns of first-course treatment received, stratified by stage
Fig. 5
Fig. 5
Kaplan–Meier analyses of OS in advanced disease (stages III-IV), stratified by first-course treatment
Fig. 6
Fig. 6
Multivariable analysis of the OS in patients with advanced disease
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cabanillas G, Montoya-Cerrillo D, Kryvenko ON, Pal SK, Arias-Stella JA 3rd. Collecting duct carcinoma of the kidney: diagnosis and implications for management. Urol Oncol. 2022;40(12):525–36. 10.1016/j.urolonc.2021.04.041. - PubMed
    1. Karakiewicz PI, Trinh QD, Rioux-Leclercq N, de la Taille A, Novara G, Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Lechevallier E, Coulange C, Valeri A, Descotes JL, Rambeaud JJ, Abbou CC, Lang H, Jacqmin D, Mejean A, Patard JJ. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol. 2007;52(4):1140–5. 10.1016/j.eururo.2007.01.070. - PubMed
    1. Sui W, Matulay JT, Robins DJ, James MB, Onyeji IC, RoyChoudhury A, Wenske S, DeCastro GJ. Collecting duct carcinoma of the kidney: Disease characteristic and treatment outcomes from the National Cancer Database. Urol Oncol. 2017;35(9):540.e13-540.e18. 10.1016/j.urolonc.2017.04.010. - PubMed
    1. Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. Clin Genitourin Cancer. 2019;17(1):46-57. e5. 10.1016/j.clgc.2018.10.002. - PMC - PubMed
    1. Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun FKH, Terrone C, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Collecting duct carcinoma: Epidemiology, clinical characteristics and survival. Urol Oncol. 2023;41(2):119.e7-110.e14. 10.1016/j.euo.2023.01.009. - PubMed

LinkOut - more resources